Orchid Pharma analysis on different parameters

Quality :- The company’s quality grade remains average, indicating a moderate level of operational efficiency and business fundamentals. Over the past five years, operating profit has expanded at an annual rate of approximately 15.6%, signalling some growth momentum. However, this growth is tempered by a relatively low return on equity, averaging 4.82%, which suggests limited profitability generated per unit of shareholders’ funds. Valuation :- Valuation remains a key factor in the recent evaluation revision. Orchid Pharma Ltd is considered very expensive relative to its capital employed, with an enterprise value to capital employed ratio of 3.5. This premium valuation contrasts with the company’s subdued profitability metrics, including a return on capital employed (ROCE) of -0.9%, which is notably low. Financial :- Financial trends for Orchid Pharma Ltd show a relatively flat trajectory in recent periods. The company reported a PAT of ₹23.78 crores for the nine months ended June 2026, reflecting a contraction of 36.38% compared to prior periods. The half-year ROCE stood at a low 1.27%, while the debt-to-equity ratio increased to 0.28 times, marking the highest level in recent history. Technical :-a technical perspective, the stock exhibits a mildly bullish stance. However, recent price movements have been volatile, with the stock declining by 2.95% on the latest trading day and showing a one-month drop of nearly 23%. Over six months, the stock has delivered a positive return of 50.27%, while the year-to-date gain stands at 11.95%, and the one-year return is approximately 17.08%.